OAM
AIMT

Oppenheimer Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Oppenheimer Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-23,498
Closed -$393K – 1139
2020
Q2 		$393K Buy
23,498
+331
+1% +$5.62K 0.01% 853
2020
Q1 		$334K Sell
23,167
-520
-2% -$13.3K 0.01% 839
2019
Q4 		$793K Buy
23,687
+6,477
+38% +$181K 0.02% 689
2019
Q3 		$360K Buy
17,210
+10,252
+147% +$209K 0.01% 887
2019
Q2 		$145K Sell
6,958
-1,107
-14% -$22.8K ﹤0.01% 1134
2019
Q1 		$180K Buy
8,065
+3,255
+68% +$76.6K ﹤0.01% 1064
2018
Q4 		$115K Buy
+4,810
New +$124K ﹤0.01% 1158

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oppenheimer Asset Management's AIMT Position: Q3 2020 in Review

Oppenheimer Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 23,498 shares — an estimated $393K sold.

Oppenheimer Asset Management first reported a position in AIMT in Q4 2018 and held it in 7 quarters. The position peaked at $793K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Oppenheimer Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Oppenheimer Asset Management sold 23,498 Aimmune Therapeutics shares in Q3 2020, an estimated $393K.
  • Oppenheimer Asset Management first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 7 quarters.
  • Oppenheimer Asset Management's Aimmune Therapeutics position peaked at $793K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Oppenheimer Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.